Truqap plus Faslodex approved in Japan for patients with advanced HR-positive breast cancer
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
The facility will manufacture tablets, capsules, and injections for the oncology segment
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
Pharma Solutions operates 10 research and development and/or production sites globally
The MDC business produces components for medical device manufacturers globally with a focus on precious metal alloys and nitinol
To accelerate the development of next-generation radioconjugates to treat cancer
A five-day inspection was concluded successfully with no critical and no major observations raised
Subscribe To Our Newsletter & Stay Updated